Chemclin Diagnostics Co., Ltd.

Equities

688468

CNE100005311

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
7.67 CNY +1.32% Intraday chart for Chemclin Diagnostics Co., Ltd. -0.65% -28.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chemclin Diagnostics Launches Homegrown Immunodetection Kits MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Chemclin Diagnostics Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023. CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Chemclin Diagnostics Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023. CI
Chemclin Diagnostics to Buy Back Up to 60 Million Yuan Shares MT
Chemclin Diagnostics Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares. CI
Chemclin Diagnostics Co., Ltd. authorizes a Buyback Plan. CI
Chemclin Diagnostics Registers Hepatitis Testing Kit MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chemclin Diagnostics Registers Antibody Testing Kit MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Chemclin Diagnostics Gets Medical Device Registration Certificate for Herpes Simplex Virus Detection Kit MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chemclin Diagnostics Gets Patent for Two Products MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chemclin Diagnostics Gets Patent for Two Analysis Kits MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chemclin Diagnostics Co., Ltd.(SHSE:688468) added to Shanghai Stock Exchange Composite Index CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Chemclin Diagnostics Co., Ltd.
More charts
Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 688468 Stock
  4. News Chemclin Diagnostics Co., Ltd.
  5. Chemclin Diagnostics Launches Homegrown Immunodetection Kits
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW